Impact of hepatocyte growth factor on the colonic morphology and gut microbiome in short bowel syndrome rat model
Topic overview
This preclinical study demonstrates that hepatocyte growth factor (HGF) administration in a rat model of short bowel syndrome modulates colonic tight junction proteins and reduces LPS-producing gut bacteria while downregulating inflammatory TLR4 signaling. Findings suggest HGF may enhance intestinal barrier function through microbiome-mediated mechanisms, offering potential therapeutic insights for SBS management.
Key takeaways
- HGF administration (0.3 mg/kg/day IV) modulates tight junction proteins in distal colon of SBS rats, potentially strengthening mucosal barrier.
- HGF treatment increases beneficial Verrucomicrobiota and reduces LPS-producing bacteria in colonic microbiome after massive small bowel resection.
- TLR4 gene expression significantly decreased in distal colon with HGF, suggesting reduced inflammatory signaling in SBS model.
- HGF effects on gut barrier and microbiome are region-specific, primarily affecting distal colon rather than proximal segments.
- HGF may offer therapeutic potential for SBS by enhancing intestinal adaptation through microbiome modulation and barrier function.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Impact of hepatocyte growth factor on the colonic morphology and gut microbiome in short bowel syndrome rat model. GlobalCastMD Medical Library. 2024-07-13. https://dev.library.globalcastmd.com/article/8848?via_space=staycurrentmd
Comments